Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights
SALT LAKE CITY, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage b...
How does Clene's Q2 2025 financial performance (e.g., R&D spend, SG&A, net loss) compare to consensus expectations and prior quarters?
What are the key risks highlighted in the earnings release that could impact the stock's upside or downside?
What potential partnership or licensing opportunities could arise from the recent updates, and how would they affect the company's growth outlook?
13 days ago